最新ニュース Nippon Steel (OTC:NPSCY) 株価情報

Nippon Steel Corporation, or NS, is the largest steel producer in Japan and one of the top five producers globally. NS supplies steel products such as steel sheets, steel plates, pipes, tubes, bars, wire rods, and stainless steels. It is mainly exposed to the auto, construction, and energy sectors. Steelmaking accounts for around 85%-90% of its revenue, while the remainder stems from engineering and construction, chemicals, new materials, and system solutions. Around 35%-40% of its revenue is from exports.

NIPPON STEEL CORP S/ADR by Nippon Steel Corporation

Nippon Steel Corp

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) with a Buy and maintains $12 price target.

News

Price Target

Reiteration

Analyst Ratings

IMRX

Needham Reiterates Buy on Immuneering, Maintains $12 Price Target

Goldman Sachs analyst Duffy Fischer maintains PPG Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) with a Buy and lowers the price target from $153 to $135.

Goldman Sachs Maintains Buy on PPG Indus, Lowers Price Target to $135

Contracts

ConocoPhillips Expects Most Of $2B Divestiture To Occur In 2025

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) with a Overweight and raises the price target from $19 to $21.

ORIC

JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $21

Glen Burnie Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBZ#NASDAQ">GLBZ</a>) reported quarterly losses of $(0.01) per share. This is a 116.67 percent decrease over earnings of $0.06 per share from the same period last year.

Earnings

GLBZ

Glen Burnie Bancorp Q4 EPS $(0.01) Down From $0.06 YoY

Goldman Sachs analyst Brian Lee maintains Mueller Water Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWA#NYSE">MWA</a>) with a Neutral and raises the price target from $26 to $29.

Goldman Sachs Maintains Neutral on Mueller Water Products, Raises Price Target to $29

Lytus Healthcare launched to transform patient care in India
Company positioned to build on revenue growth momentum
Secures strategic financing to fuel next-generation technology expansion
Mumbai, India, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lytus Technologies Holdings, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>), a leader in platform services and next-generation technology, is strengthening its position in the high-growth HealthTech sector through Lytus Healthcare, its fully owned subsidiary that is dedicated to revolutionizing patient care and healthcare accessibility in India.
With India's healthcare sector projected to grow at a 22% CAGR, Lytus Healthcare aims to bridge critical gaps in service delivery by integrating AI-driven patient management solutions with personalized, technology-enabled care pathways. The initiative aligns with Lytus' broader strategy of leveraging digital innovation to enhance essential services across its growing subscriber base of over 4 million users.
Building Momentum through Strategic Expansion
Lytus recently reported 26% revenue growth for the first half of FY2025, reflecting increased adoption of its digital platform services and strategic expansion efforts. The company continues to strengthen its portfolio across fintech, AI, and digital services while exploring new markets and revenue streams.
"Our strong revenue growth is a testament to Lytus' ability to execute on its vision and seize market opportunities," added Pandya. "We are committed to sustainable growth while investing in next-generation solutions that enhance both customer experience and shareholder value."
Strategic Financing to Support Expansion
To support its expansion initiatives, Lytus has entered into a Standby Equity Purchase Agreement (SEPA). Under this agreement, Lytus has access up to $100 million to deploy in its businesses as growth capital over the next three years.
An initial $6 million in funding has already been secured under the SEPA, providing Lytus with the flexibility to scale operations, expand its digital ecosystem, and advance HealthTech innovations.
"This financing enhances our ability to invest in high-growth sectors while maintaining operational agility," Pandya noted. "As we build on our technology-driven approach, we remain focused on creating long-term value for our shareholders and stakeholders."

Biotech

Global

General

Lytus Healthcare Launched To Transform Patient Care In India; Reports 26% Revenue Growth In H1 FY2025; Secures $6M Funding Under $100M SEPA To Deploy In Its Businesses As Growth Capital Over The Next 3-Years For Strategic Growth In HealthTech And Digital Services.

Benchmark analyst David Williams maintains Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) with a Buy and raises the price target from $40 to $42.

AOSL

Benchmark Maintains Buy on Alpha & Omega, Raises Price Target to $42

JP Morgan analyst Doug Anmuth maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Overweight and lowers the price target from $95 to $90.

UBER

JP Morgan Maintains Overweight on Uber Technologies, Lowers Price Target to $90

Goldman Sachs analyst Leah Jordan maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Buy and lowers the price target from $68 to $60.

MDLZ

Goldman Sachs Maintains Buy on Mondelez International, Lowers Price Target to $60

Goldman Sachs analyst James Yaro maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Neutral and raises the price target from $79 to $87.

Goldman Sachs Maintains Neutral on Moelis, Raises Price Target to $87

JP Morgan analyst Stephen Tusa maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Overweight and raises the price target from $87 to $100.

JP Morgan Maintains Overweight on Johnson Controls Intl, Raises Price Target to $100

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

CYTK

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Goldman Sachs analyst Toshiya Hari maintains Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) with a Neutral and lowers the price target from $200 to $132.

Goldman Sachs Maintains Neutral on Impinj, Lowers Price Target to $132

JP Morgan analyst Alexei Gogolev maintains GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) with a Overweight and raises the price target from $224 to $231.

GDDY

JP Morgan Maintains Overweight on GoDaddy, Raises Price Target to $231

Goldman Sachs analyst Christine Cho maintains Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) with a Buy and raises the price target from $56 to $64.

CAKE

Goldman Sachs Maintains Buy on Cheesecake Factory, Raises Price Target to $64

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) with a Buy and maintains $11 price target.

RXRX

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target

JP Morgan analyst Mark Strouse upgrades Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) from Underweight to Neutral and announces $5 price target.

Upgrades

AMPS

JP Morgan Upgrades Altus Power to Neutral, Announces $5 Price Target

Benchmark analyst Cody Acree reiterates ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) from Hold to Hold.

Benchmark Reiterates Hold on ARM Holdingsto Hold

Raymond James analyst Steven Seedhouse maintains Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Strong Buy and raises the price target from $122 to $125.

VKTX

Raymond James Maintains Strong Buy on Viking Therapeutics, Raises Price Target to $125

Nippon Steel Corporation (NPSCY), together with its wholly owned subsidiary Nippon Steel North America, Inc., and United States Steel Corporation (...

Nippon Steel, U.S. Steel request court set aside Biden's block of partnership

Nippon Steel, US Steel file opening brief in lawsuit to salvage deal

Nippon Steel/US Steel deal may be discussed by Trump/Japan PM in meeting - report

Steelworkers union head files motion to dismiss lawsuit by US Steel, Nippon Steel

Nippon Steel Corporation reports results

Nippon Steel hopes Trump will see US Steel deal as strengthening America

Nippon Steel Corporation 2024 Q3 - Results - Earnings Call Presentation

Nippon Steel (NPSCY) believes its proposed acquisition of U.S. Steel (X) fits with U.S. President Donald Trump's goal of a stronger U.S., Reuters' ...

Nippon Steel says U.S. Steel bid fits with Trump's goals, Reuters reports

US Steel gains on report President Trump will meet with steel firm

Shares of U.S. Steel (X) moved higher after ABC News reported, citing sources, that President Trump is meeting with the company's leaders and FedEx...

Comments

Nippon Steel

ニュース

最新ニュース Nippon Steel (OTC:NPSCY) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル